Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 390 of 1,261
  1. US 10815219

    2,4-diaminoquinazoline derivatives for inhibiting endoplasmic reticulum (ER) stress

    The Board of Regents of the University of Oklahoma · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  2. US 10815250

    AhR modulators

    IDEAYA Biosciences, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  3. US 10815276

    Cell penetrating peptides and methods of making and using thereof

    Entrada Therapeutics, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  4. US 10815271

    Structure-based peptide inhibitors of alpha-synuclein aggregation

    The Regents of the University of California · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  5. US 10815295

    Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  6. US 10815266

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  7. US 10815285

    Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  8. US 10815463

    Messenger UNA molecules and uses thereof

    ARCTURUS THERAPEUTICS, INC. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  9. US 10815455

    Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1

    Vaximm AG · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  10. US 10815480

    Modulation of alpha synuclein expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  11. US 10815483

    Compositions for modulating C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  12. US 10815485

    RNA interference in skin indications

    Phio Pharmaceuticals Corp. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  13. US 10815484

    Compositions and methods for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  14. US 10815488

    Chimeric antigen receptors targeting B-cell maturation antigen

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  15. US 10806700

    Oral dosage forms for delivery of therapeutic agents

    Covidien LP · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  16. US 10808230

    Selection methods for genetically-modified T cells

    The Board of Regents of the University of Texas System · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  17. US 10808225

    Use of PDL1 expressing cells to convert T cells into regulatory T cells

    The Government of the United States of American, as represented by the Secretary, Department of Health and Human Services · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  18. US 10808011

    Recombinant HIV-1 envelope proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  19. US 10808246

    Oligonucleotide-ligand conjugates and process for their preparation

    Alnylam Pharmaceuticals, Inc. · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  20. US 10808004

    Triterpene-glycoside as sweetener or sweetener enhancer

    Analyticon Discovery GmbH · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  21. US 10808020

    Nuclease-mediated regulation of gene expression

    Sangamo Therapeutics, Inc. · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  22. US 10807951

    mTORC1 modulators

    The Regents of the University of California · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  23. US 10806807

    TCO conjugates and methods for delivery of therapeutic agents

    The Regents of the University of California · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  24. US 10806794

    Protease inhibitors having enhanced features

    Nektar Therapeutics · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.